收入端：FY2025 公司营业收入306 亿元，同比增长13%，主要受益于医药平台业务的较快增长。分拆看，1）报告期内公司医药自营收入261亿元，同比增长10%，主要由于自营B2C 零售商品的SKU 不断丰富，同比增长33.6%至123 万，以及国补带动医疗器械增长；2）电商平台服务收入36 亿元，同比增长54%，主要受益于健康类目广告业务的注入，平台商家数同比增长35%至4.83 万，SKU 也...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.